Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK).
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26205878.
- Also identified by DOI 10.1136/thoraxjnl-2015-207326 and PMC identifier 4752622.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The UK Refractory Asthma Stratification Programme (RASP-UK) will explore novel biomarker stratification strategies in severe asthma to improve clinical management and accelerate development of new therapies. Prior asthma mechanistic studies have not stratified on inflammatory phenotype and the understanding of pathophysiological mechanisms in asthma without Type 2 cytokine inflammation is limited. RASP-UK will objectively assess adherence to corticosteroids (CS) and examine a novel composite biomarker strategy to optimise CS dose; this will also address what proportion of patients with severe asthma have persistent symptoms without eosinophilic airways inflammation after progressive CS withdrawal. There will be interactive partnership with the pharmaceutical industry to facilitate access to stratified populations for novel therapeutic studies.
Medical subject headings
- Anti-Asthmatic Agents
- Asthma
- Biomedical Research
- Disease Management
- Patient Compliance
- Risk Assessment